 SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 23, 2021 GLOBE NEWSWIRE -- InspirMed Inc., a subsidiary of TLC Nasdaq: TLC, TWO: 4152 that specializes in the development of proprietary inhalable liposome formulation programs, recently presented data on the potential advantages of inhalable liposome formulations of antiviral drugs at the 23rd International Society for Aerosols in Medicine ISAM Congress. Pharmacokinetic studies on inhalable liposomal GS-441524 named ISPM21 and inhalable liposomal hydroxychloroquine named ISPM19 showed significantly higher concentrations in the lungs than their conventional counterparts, giving ISPM21 and ISPM19 potential as prophylaxis andor treatment for COVID-19. 